Comparative Pharmacology

Head-to-head clinical analysis: GABAPENTIN ENACARBIL versus PARADIONE.

Peer-Reviewed Evidence

Differential Analysis

GABAPENTIN ENACARBIL vs PARADIONE

Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.

GABAPENTIN ENACARBIL

Anticonvulsant

Category A/B

PARADIONE

Anticonvulsant

Category C

Head-to-Head

Clinical Matrix

Mechanism of Action

Gabapentin enacarbil is a prodrug of gabapentin. It binds to the α2δ subunit of voltage-gated calcium channels, inhibiting calcium influx and reducing release of excitatory neurotransmitters such as glutamate, norepinephrine, and substance P. This modulates neuronal excitability and pain transmission.

Paradione (paramethadione) is an oxazolidinedione anticonvulsant that suppresses neuronal activity in the motor cortex by increasing the threshold for repetitive neuronal firing and reducing synaptic transmission. Its exact mechanism is unclear but involves modulation of T-type calcium channels and enhancement of GABAergic inhibition.

Clinical Dosing

Initial: 600 mg orally once daily; titrate to 600 mg three times daily; max 2400 mg/day divided three times daily.

100 mg orally three times daily; maximum 600 mg/day.

Direct Interaction

None Documented

Other Significant Interactions

Clinical Note

moderate

Gabapentin enacarbil + Venlafaxine

"The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Venlafaxine."

Clinical Note

moderate

Gabapentin enacarbil + Nefazodone

"The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Nefazodone."

Clinical Note

moderate

Gabapentin enacarbil + Stiripentol

"The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Stiripentol."

Clinical Note

moderate